Radiomics and theranostics with molecular and metabolic probes in prostate cancer: towards a personalised approach.
Luca FilippiLuca UrsoFrancesco BianconiBarbara PalumboMaria Cristina MarzolaLaura EvangelistaOrazio SchillaciPublished in: Expert review of molecular diagnostics (2023)
F-FDG, provided valuable information to select patients who are more likely to benefit from RLT and getting information on PCa grade of differentiation and aggressiveness. In spite of its high potential, PET-radiomics for PCa is still at an embryonic phase and needs further validation.
Keyphrases
- prostate cancer
- end stage renal disease
- pet ct
- ejection fraction
- positron emission tomography
- lymph node metastasis
- newly diagnosed
- computed tomography
- chronic kidney disease
- pet imaging
- small molecule
- peritoneal dialysis
- prognostic factors
- radical prostatectomy
- single molecule
- contrast enhanced
- healthcare
- patient reported outcomes
- risk assessment
- squamous cell carcinoma
- photodynamic therapy
- climate change